We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WHO prequalifies first Chinese-produced vaccine

WHO prequalifies first Chinese-produced vaccine

October 11, 2013
CenterWatch Staff

A newly accessible vaccine against Japanese encephalitis is going to protect more children in developing countries. The vaccine, manufactured in China, needs to be given in only one dose,  can be used for infants and  is less expensive than other Japanese encephalitis vaccines.

WHO has added the vaccine to its list of prequalified medicines, meaning it has given the vaccine its stamp of approval in safety and efficacy terms, and United Nations procuring agencies can now source this vaccine. This is the first Chinese-produced vaccine to be prequalified by WHO.

"This is a welcome development both in the fight to protect children in developing countries from Japanese encephalitis and in the future availability of vaccines more generally, as China is now producing vaccines up to WHO standards," said Dr. Margaret Chan, WHO director-general. "There is a huge potential for vaccine manufacture in China and we hope to see more and more Chinese vaccines become WHO prequalified. The whole world will benefit."

Japanese encephalitis, a mosquito-borne flavivirus infection, is a severe disease that involves inflammation of the brain. It is major public health problem and is endemic with seasonal distribution in parts of China, the Russian Federation's south-east and South and South-East Asia. As there is no specific treatment for Japanese encephalitis, supportive care in a medical facility is important to reduce the risk of death or disability. The disease is preventable by proven effective vaccines.

The newly accessible vaccine is available to the world now because of several years of collaboration between WHO and the authorities of China on vaccine production standards and regulation.

In March 2011, WHO announced that the national drug regulatory authority of China, the State Food and Drug Administration (SFDA) and affiliated institutions, had met WHO indicators for a functional vaccine regulatory system. Vaccine manufacturers in China became eligible to apply for WHO prequalification of vaccines, as long as their vaccines met WHO quality and safety standards.

The vaccine prequalification procedure is a service provided by WHO that guarantees individual vaccines meet international standards of quality, safety and efficacy and are appropriate for the target population. United Nations procurement agencies can only purchase vaccines that have "passed" the review process.

It is expected other Chinese manufacturers will soon follow suit and apply for prequalification of their vaccines. This is expected to have a significant, beneficial impact on global supply of vaccines of assured quality.

The close collaboration between PATH and the vaccine manufacturer over the years led to this successful prequalification. In addition, the Bill & Melinda Gates Foundation also provided support through a grant to PATH. At the upcoming GAVI Alliance Board meeting, which will be held in Cambodia in November, the GAVI Alliance will consider opening a window for financial support for Japanese encephalitis vaccine. If the board approves this, eligible countries would be able to apply for GAVI support from 2014, with UNICEF leading the international procurement efforts for the vaccine.

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing